Diabetic kidney disease: Act now or pay later: Editorial

Nephrology

Volumn 15, Issue 1, 2010, Pages 20-22

  Atkins, Robert C ^a   Zimmet, Paul ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

AWARENESS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIABETIC PATIENT; EDITORIAL; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HEALTH EDUCATION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PUBLIC HEALTH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCREENING; SOCIOECONOMICS; WORLD HEALTH ORGANIZATION;

DIABETIC NEPHROPATHIES; HUMANS;

EID: 77149158455     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01258.x     Document Type: Editorial

References (28)

1. International Diabetes Federation and International Society of Nephrology. Diabetes and Kidney Disease: Time to Act. Brussels : International Diabetes Federation, 2003.
2. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001 414 : 782 787.
3. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes. Care. 1998 21 : 1414 1431.
4. Yoon K et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006 368 : 1681 1688.
5. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In : Gan D (ed.). Diabetes Atlas, 3rd edn. Brussels : International Diabetes Federation, 2006 15 109.
6. Reutens AT, Prentice L, Atkins R. The epidemiology of diabetic kidney disease. In : Ekoé J et al. (eds). The Epidemiology of Diabetes Mellitus, 2nd edn. Chichester : John Wiley & Sons Ltd, 2008 499 518.
7. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons. In : 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda : National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007 239 254.
8. McDonald S, Excell L, Livingston B (eds). Appendix II. In : ANZDATA Registry Report 2008. Adelaide : Australia and New Zealand Dialysis and Transplant Registry, 2008 1 97.
9. Yamagata K et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin. Exp. Nephrol. 2008 12 : 1 8.
10. Lysaght M. Maintenance dialysis population dynamics: Current trends and long term implications. J. Am. Soc. Nephrol. 2002 13 : S37 40.
11. Adler A et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney. Int. 2003 63 : 225 232.
12. Retnakaran R et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006 55 (6 1832 1839.
13. Parving H et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney. Int. 2006 69 (11 2057 2063.
14. Ninomiya T et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 2009 20 (8 1813 1821.
15. Dunstan D et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes. Care. 2002 25 (5 829 834.
16. White S et al. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med. J. Aust. 2008 188 (4 204 208.
17. Whaley-Connell A et al. Diabetes mellitus and CKD awareness: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am. J. Kidney. Dis. 2009 53 (4 Suppl 4 S11 21.
18. Thomas M, Viberti G, Groop P. Screening for chronic kidney disease in patients with diabetes: Are we missing the point? Nat. Clin. Pract. Nephrol. 2008 4 (1 2 3.
19. Holman R et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008 359 (15 1577 1589.
20. Bilous R. Microvascular disease: What does the UKPDS tell us about diabetic nephropathy? Diabet. Med. 2008 25 (Suppl 2 25 9.
21. Gaede P et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008 358 (6 580 591.
22. Patel A et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007 370 : 829 840.
23. Group AC et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008 358 : 2560 2572.
24. Zoungas S et al. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from the ADVANCE trial. Diabetes. Care. 2009 32 : 2068 2074.
25. Ruggenenti P et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004 351 (19 1941 1951.
26. Parving H et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001 345 (12 870 878. (Pubitemid 34940826)
27. Lewis E et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Eng. J. Med. 2001 345 : 851 860.
28. Burney B, Kalaitzidis R, Bakris G. Novel therapies of diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 2009 18 (2 107 111.